Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L; ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team.
Podzamczer D, et al. Among authors: sanz j.
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):139-47. doi: 10.1097/QAI.0b013e31802bf122.
J Acquir Immune Defic Syndr. 2007.
PMID: 17106274
Clinical Trial.